Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 93 results:
Συντάκτης Τίτλος [ Τύπος![(Asc)](https://www.med.auth.gr/sites/all/modules/biblio/misc/arrow-asc.png)
Φίλτρα: Συντάκτης is Anastasilakis, Athanasios D [Clear All Filters]
Primary hyperparathyroidism and incidental multifocal metastatic papillary thyroid carcinoma in a man..
Arq Bras Endocrinol Metabol. 54(6), 578-82.
(2010). Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations..
Maturitas. 147, 19-25.
(2021). Periostin on the road to nonalcoholic fatty liver disease..
Endocrine. 51(1), 4-6.
(2016). Periostin and sclerostin levels in juvenile Paget's disease..
Clin Cases Miner Bone Metab. 14(2), 269-271.
(2017). Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis..
Clin Endocrinol (Oxf). 79(4), 499-503.
(2013). Papillary thyroid microcarcinoma presenting as lymph node metastasis--a diagnostic challenge: case report and systematic review of literature..
Hormones (Athens). 11(4), 419-27.
(2012). Paget's disease of bone: emphasis on treatment with zoledronic acid..
Expert Rev Endocrinol Metab. 4(5), 423-434.
(2009). Oxidized low-density lipoprotein and adiponectin levels in pregnancy..
Gynecol Endocrinol. 27(12), 1070-3.
(2011). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019). Obesity, osteoporosis and bone metabolism..
J Musculoskelet Neuronal Interact. 20(3), 372-381.
(2020). Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone..
J Bone Miner Metab. 28(1), 108-10.
(2010). Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid..
Endokrynol Pol. 63(4), 312-5.
(2012). Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study..
Metabolism. 154005.
(2019). Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications..
Diabetes Obes Metab. 24(9), 1702-1720.
(2022). Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment..
Hormones (Athens). 17(4), 573-579.
(2018). No effect of rosuvastatin in the zoledronate-induced acute-phase response..
Calcif Tissue Int. 88(5), 402-8.
(2011). No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial..
Clin Endocrinol (Oxf). 70(4), 522-6.
(2009). Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?.
Calcif Tissue Int. 103(1), 107-108.
(2018). Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity..
Metabolism. 71, 198-201.
(2017). Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab..
Ther Clin Risk Manag. 8, 295-306.
(2012). Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study..
J Clin Med. 12(16),
(2023). Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid..
J Clin Endocrinol Metab. 101(9), L89-90.
(2016). Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate..
Rheumatol Int. 33(11), 2917-20.
(2013). Irisin in patients with nonalcoholic fatty liver disease..
Metabolism. 63(2), 207-17.
(2014). Irisin in nonalcoholic fatty liver disease: Need for an updated meta-analysis..
Metabolism. 121, 154818.
(2021).